600267 海正药业
2025/12 -
人民幣(K¥)

变动
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入10,549,6412.03%10,052,57811,379,00811,572,03911,354,396
减:营业总成本9,450,690-1.25%9,822,17410,603,99710,932,53110,761,673
    其中:营业成本5,819,865-2.19%5,876,5756,347,0066,626,5776,441,030
               财务费用84,036-34.83%191,673262,748331,253412,503
               资产减值损失(213,172)-2.67%(285,522)(126,037)(109,431)(75,337)
公允价值变动收益(34,783)133.03%278(107,318)(17,769)731
投资收益(36,698)-123.31%74,30431,079104,26434,437
    其中:对联营企业和合营企业的投资收益(26,177)-603.21%(60,373)(157,554)(75,745)(33,679)
营业利润867,03620.20%89,443682,478700,070776,864
利润总额815,37613.55%(82,867)683,423644,191904,142
减:所得税费用267,890111.34%14,148192,188133,272180,975
净利润547,486-7.41%(97,015)491,234510,919723,167
减:非控股权益6,778-168.67%(3,844)2,37423,743305,973
股东净利润540,708-10.06%(93,171)488,860487,177417,194

市场价值指针
每股收益 (元) *0.460-11.54%-0.0800.4200.4300.430
每股派息 (元) *0.2100.00%--0.1700.1400.050
每股净资产 (元) *7.1803.19%6.4256.3855.7486.917
审计意见 #标准无保留意见保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容